Q2 Results: Lupin Posts Rs 127-Crore Loss On Exceptional Items
Bottles of Duloxetine delayed-release capsules sit in a tray inside the packaging unit at the Lupin Ltd. pharmaceutical plant in Salcette. (Photographer: Dhiraj Singh/Bloomberg)

Q2 Results: Lupin Posts Rs 127-Crore Loss On Exceptional Items

Lupin Ltd. reported a surprise loss during the quarter ended September as exceptional items worth Rs 546 crore weighed on the drugmaker’s bottom line.Net loss of India’s third-largest pharmaceutica...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.